Seer, Inc. Reports Modest Revenue Growth in Q3 2025
Seer, Inc. reported Q3 2025 revenue of $4.1 million, a modest increase from the previous year. The company achieved a gross profit of $2.1 million with a 51% gross margin, while operating expenses decreased to $21.5 million. Despite a net loss of $18.2 million, improved from $21.3 million last year, Seer ended the quarter with $251.2 million in cash. The company maintains its 2025 revenue guidance of $17 million to $18 million, anticipating a 24% growth over 2024, driven by demand for its Proteograph Product Suite.
Seer, Inc. ( (SEER) ) has released its Q3 earnings. Here is a breakdown of the information Seer, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Seer, Inc., a leader in deep, unbiased proteomics, offers advanced solutions for biological insights through its Proteograph Product Suite, catering to the research sector.
In its third-quarter 2025 financial report, Seer, Inc. announced a revenue of $4.1 million, marking a modest increase from the previous year. The company highlighted a record number of third-party publications and significant demand for its Proteograph ONE workflow, underscoring its growing influence in the proteomics field.
Key financial metrics revealed a gross profit of $2.1 million with a 51% gross margin. Operating expenses saw a notable decrease to $21.5 million, driven by reduced stock-based compensation and other business costs. Despite these improvements, the company reported a net loss of $18.2 million, a reduction from the previous year’s $21.3 million loss. Seer ended the quarter with a strong cash position of $251.2 million.
Looking ahead, Seer maintains its revenue guidance for 2025, expecting growth between $17 million and $18 million, reflecting a 24% increase over 2024. The company’s management remains optimistic about the continued adoption of its technologies and its strategic direction in the proteomics market.
